MedTrace Logo

Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty

NCT06244498 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2024-02-06

No results posted yet for this study

Summary

This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.

Conditions

  • Metastases to Bone

Interventions

DRUG

Tranexamic acid injection

Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.

Sponsors & Collaborators

  • Piotr Biega

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2021-12-31
Completion
2022-12-31
FDA Drug
Yes

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06244498 on ClinicalTrials.gov